- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05421468
Timing of Thyroxine Dose In Ramadan
Timing of Thyroxine Dose In Ramadan; a Randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To date there is debate regarding the best timing of L-thyroxine administration during Ramadan as sufficient evidence is lacking. This study aims to compare two-time points of levothyroxine intake during Ramadan focusing on change in TSH, satisfaction and compliance.
A prospective, randomized, open label, multicenter Study. The first group will be will be instructed to take their L-thyroxin dose as per current guidlines at breaking of fast time (sunset) with sip of water then wait 30-60 minutes to consume Iftar meal. The second group (pre-Fajer prayer), patients are going to be instructed to take L-thyroxin dose immediately before start of fast, i.e. Alfajer (dawn) regardless of Suhoor time. The values of Thyroid stimulating hormone (TSH) will be measured two weeks before Ramadan, and 2-4 weeks after Ramadan for comparison.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jeddah, Saudi Arabia, 21423
- Recruiting
- Reem Alamoudi
-
Contact:
- Reem Alamoudi
- Phone Number: 0122266666
- Email: amoudir@ngha.med.sa
-
Sub-Investigator:
- Samah Nawar, MD
-
Sub-Investigator:
- Hiba Alharbi, MD
-
Sub-Investigator:
- Abdullah Alzahrani, MD
-
Principal Investigator:
- Ali Alqarni, MD
-
Principal Investigator:
- Yousef Saleh, MD
-
Sub-Investigator:
- Anwar Borai
-
Sub-Investigator:
- Majed Ramadan, PhD
-
Jeddah, Saudi Arabia
- Recruiting
- KingAbullahIMRC
-
Contact:
- Reem M Alamoudi
- Phone Number: 966505641595
- Email: amoudir@ngha.med.sa, refal2001@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Saudi patient (males and female) above 18 years with Primary hypothyroidism on levothyroxine replacement who are willing to fast during Ramadan.
- Patients with controlled thyroid function for last 3 months on same dose of levothyroxine.
Exclusion Criteria:
- Pregnant or lactating women.
- Uncontrolled thyroid function test three months prior Ramadan.
- Thyroid cancer patients who require suppressed TSH.
- Central Hypothyroidism, patient with acute illness.
Patients diagnosed with malabsorption i.e., Celiac Disease, Short bowel, Bariatric surgeries
- Use of certain Medications like systemic glucocorticoids, activated charcoal, sucralfate, aluminum hydroxide antacid, bile acid sequestrants, iron, calcium carbonate, PPI, rifampicin, and antiepileptic medications
- Renal or hepatic disease:
- Creatinine clearance <0.6 ml/s or serum creatinine ≥200 μmol/l
- Alanine transferase ≥2.5 times the upper limit of normal
- Active liver disease including jaundice, chronic hepatitis, previous liver transplant
- Unwillingness to be randomized or to sign informed consent
- Known Psychiatric Disorders
- Known uncontrolled substance abuse or alcoholism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Pre-Iftar (Breaking the fast)
To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).
|
Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
|
EXPERIMENTAL: Pre-Fajr (Starting the fast)
To take thyroxine immediately before start of fast at predawn time regardless of last meal time.
|
Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thyroid function
Time Frame: 6 - 8 weeks
|
Change in TSH level
|
6 - 8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICT22J-001-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypothyroidism
-
Kerman University of Medical SciencesCompletedPrediction Hypothyroidism Patients Using Machine Learning Algorithms | Identification of Important Symptoms of HypothyroidismIran, Islamic Republic of
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingHypothyroidism; IrradiationItaly
-
Cooperativas Lacteas UnidasGalician South Health Research InstituteNot yet recruitingSubclinical HypothyroidismSpain
-
IBSA Institut Biochimique SACompletedHypothyroidism;PostablativeUnited States
-
Peking Union Medical College HospitalBeijing Municipal Science & Technology CommissionCompletedSubclinical HypothyroidismChina
-
University Hospital DubravaRecruitingHypothyroidism PrimaryCroatia
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemCompletedSubclinical HypothyroidismUnited States
-
University of Colorado, DenverCharite University, Berlin, GermanyTerminatedHypothyroidism | Postsurgical HypothyroidismUnited States
-
AbbottDimension ResearchCompletedSubclinical HypothyroidismPakistan
Clinical Trials on L-Thyroxine time B (5-15 minutes Before dawn)
-
Abramson Cancer Center of the University of PennsylvaniaCompletedAdenocarcinoma | Rectal Cancer | Metastasis | Colon CancerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1United States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade... and other conditionsUnited States